about
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor.Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial.Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.Head and neck tumors other than squamous cell carcinoma.Advances in the changing patterns of aetiology of head and neck cancers.Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status.Major and minor salivary gland tumors.Management of salivary gland tumors.RET inhibition: implications in cancer therapy.Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature.Emerging tyrosine kinase inhibitors for head and neck cancer.Occupation and cancer of the larynx: a systematic review and meta-analysis.Fosbretabulin for the treatment of anaplastic thyroid cancer.Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review.Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer.Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy.Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma.Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients.Multikinase inhibitors in thyroid cancer.Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report.Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer.Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study.Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma.Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer.TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer.Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland.
P50
Q30650708-1A2B8C6E-27E4-45AC-9026-5AAE517BB738Q30820418-74C97130-60A8-4998-8EC2-C294F3D30ABDQ34658767-81CE7DB1-E3C9-4EC4-B5D3-836BF1EE14E0Q34989774-4A35CB2B-8F7A-4C6C-AA75-3BEAD9961EDCQ35740075-67E2E460-A692-40DB-97BA-67770240F4A7Q36427965-2E89933B-69A2-4159-AF18-6CB1A6CF91F2Q37541446-BBEE6BB9-A562-4169-A501-17458A21606BQ37638875-79AC8B8A-B7B1-4150-8C5F-2605068B9796Q38055494-498F9061-CCFE-40B6-B271-4A6336111E97Q38086590-9B03DB8F-BA81-4FC9-AB10-78EBD34A9FC6Q38089549-29FEE764-883E-4122-A527-2FE15745B055Q38149327-D4A1CF60-091E-4191-B7B3-9D9CFE8A8FDDQ38259733-185EFE47-297E-46D5-A725-A4E7A7567567Q38268163-E81F2AD6-5574-4156-9DC2-A76F8E61F0D5Q38282447-9316FB61-B234-447A-8AEA-2540BD78AE88Q39015086-F8FAC8A2-08DC-4FAA-A8D2-971978EFB725Q39156639-4373FEEB-3DF8-42FC-ABBD-E225EDF988B6Q39253334-A7FF4FD8-B141-454F-83FF-B5A7AEEAD266Q39501001-822A1970-5A9D-46D0-BEB0-7D558250DB9EQ39587841-8088F7E0-F2A3-414B-846E-24E22C4E7625Q39737306-97A95A86-F1D6-4558-BA15-72AE1455619FQ39919172-800833D7-D84B-4D3A-8E67-F403EA2D07E6Q39964625-72A81100-5BFB-4485-9132-65B7F20B06F1Q40020541-961E6181-2985-491E-897F-826E5DD0CDF9Q40099914-EFA96DEA-420D-4A00-B95E-331AC84452D3Q40452694-2974182B-BF49-4D12-BBEB-89AEE9A11334Q40485928-8D9E36E1-5B97-488A-B56A-1A45973ED899Q40501848-5CDA6DDE-93DB-4DC3-9A40-1E62E1EA9F37Q40539847-2F899EE3-4029-437E-908E-DD2C5EFF5BF7Q41496425-908AC5F9-7509-4001-BB42-26DDF86ED7FFQ41605972-0ACC26DC-958A-427B-9E25-0BA30BCB07CDQ41658902-E0019757-C726-4F2C-B021-3EEB5F47E117Q42434702-442F6136-245F-49D2-A25E-52AE8D5A3683Q42461792-9DBE9D23-C914-4FC8-BA3C-A436417C0DB5Q43202682-57BDFDD6-D79F-4BD7-9AEF-96978FBF6A79Q43889222-C3CD8BEA-5C6A-42AA-B9E9-313FA1192B11Q44267072-DDC9D926-DEC8-4232-89A3-DD215BA70768Q44323210-4C4E0F45-1723-434E-A319-7EDF8958E0B2Q44480773-FF373736-D5EF-4426-8ED0-E9AD0412B801Q44525947-ACDF97A4-2FC9-4162-935D-825E5748220D
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Laura D. Locati
@ast
Laura D. Locati
@en
Laura D. Locati
@es
Laura D. Locati
@nl
Laura D. Locati
@sl
type
label
Laura D. Locati
@ast
Laura D. Locati
@en
Laura D. Locati
@es
Laura D. Locati
@nl
Laura D. Locati
@sl
prefLabel
Laura D. Locati
@ast
Laura D. Locati
@en
Laura D. Locati
@es
Laura D. Locati
@nl
Laura D. Locati
@sl
P1053
B-8163-2017
P106
P1153
6603629362
P21
P214
111148207983600342806
P31
P3829
P496
0000-0003-3315-2580
P734
P735
P7859
viaf-111148207983600342806